Menu
Back to Journals » Biologics: Targets and Therapy » Volume 2 » Issue 2
Biologics: Targets and Therapy
ISSN: 1177-5491
- View all (502)
- Volume 18, 2024 (6)
- Volume 17, 2023 (17)
- Volume 16, 2022 (18)
- Volume 15, 2021 (40)
- Volume 14, 2020 (13)
- Volume 13, 2019 (17)
- Volume 12, 2018 (19)
- Volume 11, 2017 (14)
- Volume 10, 2016 (18)
- Volume 9, 2015 (17)
- Volume 8, 2014 (27)
- Volume 7, 2013 (28)
- Volume 6, 2012 (46)
- Volume 5, 2011 (9)
- Volume 4, 2010 (31)
- Volume 3, 2009 (45)
- Volume 2, 2008 (89)
- Volume 1, 2007 (48)
Archive: Volume 2, 2008
Neuroprotection of lamotrigine on hypoxic-ischemic brain damage in neonatal rats: Relations to administration time and doses
Yong-Hong Yi, Wen-Chao Guo, Wei-Wen Sun, Tao Su, Han Lin, et al
Biologics: Targets and Therapy 2008, 2:339-344
Published Date: 6 June 2008
Heterogeneous gene expression changes in colorectal cancer cells share the WNT pathway in response to growth suppression by APHS-mediated COX-2 inhibition
Bostjan Humar, Les McNoe, Anita Dunbier, Rosemary Heathcott, Antony W Braithwaite, Anthony E Reeve
Biologics: Targets and Therapy 2008, 2:329-337
Published Date: 6 June 2008
Cognitive performance and the thymus among HIV-infected subjects receiving HAART
Maria J Miguez-Burbano, John E Lewis, Jose Moreno, Joel Fishman
Biologics: Targets and Therapy 2008, 2:321-327
Published Date: 6 June 2008
Review of the use of idursulfase in the treatment of mucopolysaccharidosis II
T Andrew Burrow, Nancy D Leslie
Biologics: Targets and Therapy 2008, 2:311-320
Published Date: 6 June 2008
Mycophenolate mofetil in the treatment of lupus nephritis
Patrick FK Yong, David P D’Cruz
Biologics: Targets and Therapy 2008, 2:297-310
Published Date: 6 June 2008
Severe congenital protein C deficiency: the use of protein C concentrates (human) as replacement therapy for life-threatening blood-clotting complications
Paul N Knoebl
Biologics: Targets and Therapy 2008, 2:285-296
Published Date: 6 June 2008
Natalizumab in the treatment of Crohn’s disease
Danila Guagnozzi, Renzo Caprilli
Biologics: Targets and Therapy 2008, 2:275-284
Published Date: 6 June 2008
Selenium and thyroid autoimmunity
Roberto Negro
Biologics: Targets and Therapy 2008, 2:265-273
Published Date: 6 June 2008
Strategies for regenerating injured axons after spinal cord injury – insights from brain development
Masaki Ueno, Toshihide Yamashita
Biologics: Targets and Therapy 2008, 2:253-264
Published Date: 6 June 2008
Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences
Matthew L Stoll, Alisa C Gotte
Biologics: Targets and Therapy 2008, 2:229-252
Published Date: 6 June 2008
Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab
George P Kim, Axel Grothey
Biologics: Targets and Therapy 2008, 2:223-228
Published Date: 6 June 2008
Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents
Antonio M Risitano, Bruno Rotoli
Biologics: Targets and Therapy 2008, 2:205-222
Published Date: 6 June 2008
Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance
Jennifer S Carew, Steffan T Nawrocki, Francis J Giles, John L Cleveland
Biologics: Targets and Therapy 2008, 2:201-204
Published Date: 6 June 2008
Natalizumab for the treatment of relapsing multiple sclerosis
Richard A Rudick, Michael A Panzara
Biologics: Targets and Therapy 2008, 2:189-199
Published Date: 6 June 2008
The role of basiliximab in the evolving renal transplantation immunosuppression protocol
Paola Salis, Chiara Caccamo, Roberto Verzaro, Salvatore Gruttadauria, Mary Artero
Biologics: Targets and Therapy 2008, 2:175-188
Published Date: 6 June 2008
Update on the use of etanercept across a spectrum of rheumatoid disorders
Bernard Combe
Biologics: Targets and Therapy 2008, 2:165-173
Published Date: 6 June 2008